Loading…
ACETAZOLAMIDE DAWA is a brand name for Acetazolamide. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Acetazolamide Tablets are for oral administration. Acetazolamide is an enzyme inhibitor which acts specifically on carbonic anhydrase. It is indicated in the treatment of: • Glaucoma: Acetazolamide Tablets is useful in glaucoma (chronic simple (open angle) glaucoma, secondary glaucoma, and perioperatively in acute…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology • Glaucoma (simple acute congestive and secondary):
Adults: 250 - 1,000mg (1-4 tablets) per 24 hours, usually in divided doses for amounts over 250mg daily. • Abnormal retention of fluid: Congestive heart failure, drug-induced oedema.
Adults:
For diuresis, the starting dose is usually 250 - 375mg (1-1½ tablets) once daily in the morning. If, after an initial response, the patient fails to continue to lose oedema fluid, do not increase the dose but allow for kidney recovery by omitting a day.
Best results are often obtained on a regime of 250 - 375mg (1-1½ tablets) daily for two days, rest a day, and repeat, or merely giving the Acetazolamide tablets every other day. g. digitalis, bed rest and salt restriction in congestive heart failure and proper supplementation with elements such as potassium in drug-induced oedema.
For cases of fluid retention associated with pre-menstrual tension, a daily dose (single) of 125 - 375mg is suggested. • Epilepsy: Adults: 250 - 1,000mg daily in divided doses. Children: 8-30mg/kg in daily divided doses and not to exceed 750mg/day.
The change from other medication to Acetazolamide tablets should be gradual.
Elderly:
Acetazolamide tablets should only be used with particular caution in elderly patients or those with potential obstruction in the urinary tract or with disorders rendering their electrolyte balance precarious or with liver dysfunction.
Method of administration Oral
The following adverse reactions are classified by system organ class and ranked under heading of frequency using the following convention: Not known: frequency cannot be estimated from the available data System organ class Frequency Adverse reactions Blood and lymphatic system disorders Not known Thrombocytopaenia, Leukopenia, Aplastic anaemia, Bone marrow depression, Pancytopenia, Agranulocytosis**** Ear and labyrinth disorders Not known Impaired hearing and tinnitus Eye disorders Not known Choroidal effusion, choroidal detachment, Transient myopia*** Gastrointestinal disorders Not known Melaena, Taste disturbance, Nausea, Vomiting, Diarrhoea General disorders and administration site conditions Not known Fever****, Fatigue, Anaphylaxis****, Flushing Hepatobiliary disorders Not known Fulminant hepatic necrosis****, Hepatitis or cholestatic jaundice Investigations Not known Abnormal liver function Metabolism and nutrition disorder Not known Metabolic acidosis, electrolyte imbalance* and thirst** Nervous system disorders Not known Paraesthesia, particularly a “tingling” feeling in the extremities, Dizziness, Headache, Occasional instances of drowsiness, Convulsions, Flaccid paralysis Psychiatric disorders Not known Depression, Irritability, Reduced libido, Occasional instances of confusion Renal and urinary disorders Not known Haematuria, Crystalluria****, Renal and ureteral colic****, Renal lesions, Renal failure, Calculus formation****, Glycosuria, Polyuria Respiratory, thoracic and mediastinal disorders Not known Non-cardiogenic pulmonary oedema Skin and subcutaneous tissue disorders Not known Urticaria, Rash (including Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis)****, Thrombocytic purpura, Photosensitivity, Acute generalised exanthematous pustulosis (AGEP) *During long-term therapy, metabolic acidosis and electrolyte imbalance may occasionally occur.
This can usually be corrected by the administration of bicarbonate. **Adverse reactions during short-term therapy are usually non-serious. ***This condition invariably subsides upon diminution or withdrawal of the medication. ****Acetazolamide is a sulphonamide derivative and therefore some side effects similar to those caused by sulphonamides have occasionally been reported.
Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour.
The mechanism of this risk is not known and the available data does not exclude the possibility of an increased risk for Acetazolamide. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paraesthesia.
Increasing the dose often results in a decrease in diuresis. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure diuresis in complete refractory failure. When Acetazolamide tablets is prescribed for long-term therapy, special precautions are advisable.
The patient should be cautioned to report any unusual skin rash. Periodic blood cell counts and electrolyte levels are recommended. Fatalities have occurred, although rarely, due to severe reactions to sulphonamides. A precipitous drop in formed blood cell elements or the appearance of toxic skin manifestations should call for immediate cessation of Acetazolamide tablets therapy.
8). Non- cardiogenic pulmonary oedema typically developed within minutes to hours after acetazolamide intake. Symptoms included dyspnoea, hypoxia, and respiratory insufficiency. If non-cardiogenic pulmonary oedema is suspected, acetazolamide should be withdrawn, and supportive treatment should be given.
Acetazolamide should not be administered to patients who previously experienced non-cardiogenic pulmonary oedema following acetazolamide intake. In patients with pulmonary obstruction or emphysema where alveolar ventilation may be impaired, Acetazolamide tablets may aggravate acidosis and should be used with caution.
1. Acetazolamide is contra-indicated in situations in which sodium and/or potassium blood levels are depressed, in cases of marked kidney and liver disease or dysfunction, suprarenal gland failure, and hyperchloremic acidosis. Acetazolamide tablets should not be used in patients with hepatic cirrhosis as this may increase the risk of hepatic encephalopathy.
Long-term administration of Acetazolamide tablets is contra-indicated in patients with chronic non-congestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.
Acetazolamide tablets should not be used in patients hypersensitive to sulphonamides.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Acetazolamide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects, you can help provide more information on the safety of this medicine.
In patients with a past history of renal calculi, benefit should be balanced against the risks of precipitating further calculi. 8). In case of AGEP diagnosis, acetazolamide should be discontinued and any subsequent administration of acetazolamide contraindicated.
Cases of choroidal effusion/detachment have been reported after the use of acetazolamide. Symptoms include acute onset of decreased visual acuity or ocular pain and can occur within hours after initiation of acetazolamide treatment.
If choroidal effusion/detachment is suspected, acetazolamide should be discontinued as rapidly as possible. Lactose Acetazolamide tablets contain Lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.